Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

China's WuXi AppTec nine-month revenue rises on chemistry segment growth; lifts 2026 outlook

By Reuters News


Overview

  • China pharma R&D services firm's nine-month revenue rose 39% year-over-year

  • Adjusted non-IFRS net profit attributable to owners increased sharply year-over-year

  • Company raised full-year revenue and adjusted free cash flow guidance for 2026


Outlook

  • WuXi AppTec raises 2026 total revenue guidance to RMB61.0-61.9 bln from RMB58.5-60.5 bln

  • Company now expects 2026 continuing operations revenue to grow 40%-42% YoY

  • WuXi AppTec raises 2026 adjusted free cash flow forecast to RMB14.5-15.5 bln from RMB13.5-14.5 bln


Result Drivers

  • CHEMISTRY SEGMENT - Co said strong growth in WuXi Chemistry was driven by pipeline progression to late stages and ramp-up of new capacity

  • TIDES MODALITIES - Co said rapid growth in TIDES business was supported by increased customer and molecule counts

  • DRUG SAFETY SERVICES - Co said drug safety evaluation services contributed to WuXi Testing segment growth


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

9M Revenue

RMB 45.54 bln

9M Net Income Attributable

RMB 19.16 bln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for WuXi AppTec Co., Ltd. is CNY185.25, about 26.9% above its October 26 closing price of CNY146.00

  • The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 19 three months ago


Reuters Recommended Reads

  • Oct 23 - Bristol Myers, SystImmune breast cancer drug cuts progression risk in study

  • Oct 23 - Revolution's Rasonque improves survival across subgroups in pancreatic cancer patients

  • Oct 26 - China's yuan climbs to fresh 4-year high ahead of key policy meetings


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.